National Jewish Health: Study Shows Benralizumab is Effective as a Treatment for Eosinophilic Granulomatosis With Polyangiitis, a Rare Form of Vasculitis
February 24, 2024
February 24, 2024
DENVER, Colorado, Feb. 24 (TNSres) -- National Jewish Health, a respiratory hospital, issued the following news release on Feb. 23, 2024:
Researchers have shown that the drug benralizumab is as effective and safe as mepolizumab for inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) according to a study published today in The New England Journal of Medicine. The results of the non-inferiority study were presented at the American Academy of Allerg . . .
Researchers have shown that the drug benralizumab is as effective and safe as mepolizumab for inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) according to a study published today in The New England Journal of Medicine. The results of the non-inferiority study were presented at the American Academy of Allerg . . .